Symbols

IRMD

Iradimed·NASDAQ

--(--)

IRMD fundamentals

IRMD Q4 2025 Earnings

Iradimed (IRMD) released its earnings on Feb 10, 2026: revenue was 22.69M (YoY +17.03%), beat estimates; EPS was 0.54 (YoY +22.73%), beat estimates.

Revenue / YoY

22.69M

+17.03%

EPS / YoY

0.54

+22.73%

Report date

Feb 10, 2026

IRMD Earnings Call Summary for Q4,2025

Record Growth: Q4 2025 revenue up 17% YoY to $22.7 million, with full-year revenue of $83.8 million (+14% YoY).
3870 Launch Momentum: 10%-14% ASP increase expected, targeting $50 million annual run rate from 2,000+ U.S. channels.
Replacement Opportunity: 6,400+ outdated 3860 pumps in the U.S. present a multi-year replacement pipeline.
Gross Margin Expansion: 77% full-year margin with potential H2 2026 improvement.
International Expansion: Europe CE mark by end-2026, Japan approval targeted for mid-2027.

Earnings

EPS

Revenue

Revenue & Expenses

IRMD has released its 2025 Q4 earnings report, with revenue of 22.69M, reflecting a YoY change of 17.03%, and net profit of 6.44M, showing a YoY change of 25.17%. The Sankey diagram below clearly presents IRMD's revenue sources and cost distribution.

Key Indicators

Iradimed (IRMD) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Iradimed (IRMD)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Iradimed (IRMD)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Iradimed (IRMD)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown